ipilimumab,nivolumab
bms
['ipilimumab', 'nivolumab', 'nivo', 'rcc,(-irccs),(-srcc),(-urcc)']
distinct outcomes in hispanic/latinx and non-hispanic/latinx patients with metastatic #rcc treated with first-line ipilimumab + nivolumab. presented by sana ali, md . #asco22 written coverage by &gt; 
Largest global online community of #urological medical professionals & patients. #AUA22 #bladdercancer #menshealth #prostatecancer #kidneycancer #Urology